Rhaeos Secures $20M in Seed Funding for Breakthrough Medical Device Technology: FlowSense

Rhaeos, a clinical-stage medical device company that is transforming the landscape of patient monitoring, has announced an impressive funding round, successfully raising $20 million to continue its pioneering efforts in noninvasive health technology. The company focuses on developing FlowSense, a groundbreaking platform technology that consists of a wireless, wearable skin patch designed to assess and monitor subdermal fluid flow throughout the body. Initial applications target hydrocephalus, a life-threatening condition characterized by an abnormal accumulation of cerebrospinal fluid (CSF). Traditional treatment methods, primarily the use of implantable shunts, often fail, resulting in repeated emergency room visits and multiple surgeries due to the inability to effectively monitor CSF flow. FlowSense aims to change that narrative by providing real-time data regarding CSF flow, transmitted wirelessly to a proprietary mobile app, all without the need for complex capital equipment. Its thin, bandage-like design ensures comfort and ease of use for patients. Rhaeos has garnered significant recognition for FlowSense, receiving FDA breakthrough designation and over $7.5 million in funding from the NIH and NSF. With published clinical data in prestigious journals like Science and Nature, the company is poised for initial market entry in 2024. With this new funding, Rhaeos is not only set to enhance the safety and care standards for hydrocephalus patients but is also actively developing follow-on products targeting additional chronic conditions. This funding announcement marks a significant step forward for Rhaeos as it continues to innovate and lead in the field of wearable medical technology.